DOCSLIB.ORG

Involvement of Estrogen Receptor &Beta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Involvement of Estrogen Receptor &Beta Molecular Psychiatry (2013) 18, 674 -- 680 & 2013 Macmillan Publishers Limited All rights reserved 1359-4184/13 www.nature.com/mp ORIGINAL ARTICLE Involvement of estrogen receptor b in maintenance of serotonergic neurons of the dorsal raphe H Suzuki1, RPA Barros1, N Sugiyama1, V Krishnan2, BC Yaden3, H-J Kim1, M Warner1,4 and J-Å Gustafsson1,2 The serotonergic neurons of the dorsal raphe (DR) nucleus in the CNS are involved in fear, anxiety and depression. Depression and anxiety occur quite frequently in postmenopausal women, but estrogen replacement to correct these CNS disorders is at present not favored because estrogen carries with it an increased risk for breast cancer. Serotonin synthesis, release and reuptake in the DR are targets of pharmaceuticals in the treatment of depression. In the present study we have examined by immunohistochemistry, the expression of two nuclear receptors, that is, the estrogen receptors ERa and ERb. We found that ERb but not ERa is strongly expressed in the DR and there is no sex difference and no change with ageing in the number of tryptophan hydroxylase (TPH)-positive neurons in the DR of wild-type (WT) mice. However, in ovariectomized (OVX) WT and in ERbÀ/À mice, there was a marked reduction in the number of TPH-positive normal-looking neurons and a marked increase in TPH-positive spindle-shaped cells. These neuronal changes were prevented in mice 1--3 weeks (but not 10 weeks) after OVX by the selective ERb agonist, LY3201, given as continuous release pellets for 3 days. The ERb agonist had no effects on glucose homeostasis. Thus, the onset of action of the ERb agonist is rapid but there is a limited window in time after estrogen loss when the drug is useful. We conclude that, rather than estradiol, ERb agonists could be useful pharmaceuticals in maintaining functional DR neurons to treat postmenopausal depression. Molecular Psychiatry (2013) 18, 674--680; doi:10.1038/mp.2012.62; published online 5 June 2012 Keywords: LY3201; postmenopausal depression; tryptophan hydroxylase INTRODUCTION ligand, 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), is diabeto- 13 Estrogen receptor (ER) b is widely expressed in the developing genic, we have examined the effects of LY3201 on glucose mouse brain and is essential for the correct layering of the homeostasis. cortex.1--3 With immunohistochemical techniques, ERb expression has been studied in several laboratories.4 There is little or no ERb expression in adult pituitary5,6 or in the endometrium,5 whereas in MATERIALS AND METHODS the mammary gland ERb is abundant and has antiproliferative, Animals pro-differentiative effects.7 In contrast to developing mouse brain WT, ERbÀ/À and ERaÀ/Àmice were generated as previously described.14--16 where ERb is abundant, in adults, expression of ERb is confined to All mice were backcrossed to a C57BL6 background for at least 10 few areas of the brain. Owing to lack of ERb expression in the generations. Animals were housed on a 12-h light/dark cycle under pituitary, selective ERb agonists do not interrupt the hypothala- controlled temperature (20--22 1C) and fed a standard pellet diet with mo--pituitary--gonadal axis, nor do they cause growth of the water provided ad libitum. For brain collection, mice were deeply mammary gland or uterus.5,8 anesthetized with carbon dioxide and perfused manually using gravity It has been known for some time that ERa is not expressed in through left ventricle with phosphate-buffered saline followed by 4% the serotonergic neurons of the dorsal raphe (DR) but that paraformaldehyde. Brains were dissected and postfixed in the same estrogen influences the serotonergic system.9 For many years, the fixative overnight at 4 1C and were processed for 5-mm paraffin sections. effects of estrogen on the DR were thought to be indirect. This To examine glucose homeostasis, skeletal muscle and white adipose view had to be revised after the discovery of ERb in 1996 and the tissue were excised, frozen immediately for real-time quantitative PCR and finding in several laboratories of the expression of ERb in neurons blood was collected from the orbital sinus for serum metabolic panel 10,11 of the DR. E2 is equally potent on ERa and ERb, but agonists measurements. selective for ERa or ERb have been synthesized. We have obtained one ERb-selective agonist from the pharmaceutical company Eli Ovariectomy and treatment with E2 or LY3201 Lilly (LY3201) and shown that it is anxiolytic.12 At the age of 6 months, 45 WT mice were ovariectomized (OVX) bilaterally In the present study we have examined the expression of ERb in through a single dorsal midline incision across the lumbar region, making the DR of (wild-type) WT mice and the consequences to the DR both ovaries accessible. The ovary-attached fat pad was gently grasped to neurons of loss of ERb. In addition, we have investigated the lift and exteriorize the ovary. Subsequently, the periovarian sac was peeled effects of LY3201 on tryptophan hydroxylase (TPH) in the DR back over the surface of the ovary, allowing removal of the whole ovary. and, as we have previously reported that one ERb-seletive This surgery was performed at Jackson Laboratory (Sacramento, CA, USA). 1Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX, USA; 2Musculoskeletal Research, Lilly Research Laboratories, Indianapolis, IN, USA; 3Department of Biology, IUPUI, Indianapolis, IN, USA and 4Department of Biosciences and Nutrition, Karolinska Institutet, Novum, Stockholm, Sweden. Correspondence: Professor J-Å Gustafsson, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, 3605 Cullen Boulevard, Houston 77204, TX, USA. E-mail: [email protected] Received 31 January 2012; revised 5 March 2012; accepted 8 March 2012; published online 5 June 2012 Estrogen receptor b in the dorsal raphe H Suzuki et al 675 1, 3 and 10 weeks after OVX, mice were randomly placed in three groups release), Innovative Research of America, Sarasota, FL, USA); and (3) five mice as follows: (1) five mice were inserted with placebo pellets; (2) five mice were were inserted with LY3201 pellets (200 mgkgÀ1 per day, Eli Lilly, Indianapolis, À1 inserted with E2 pellets (10 mgkg per day, 6.3 mg per pellet for 21-day IN, USA) subcutaneously. Hormonal treatment lasted for 3 days. a ER b ER Figure 1. Expression of estrogen receptors (ERs) in the dorsal raphe (DR) nucleus of 6-month-old male mice. Several ERa-positive cells are found in the periaqueductal gray (PAG) but not in the DR (a). Many ERb-positive neurons are found in the DR (b). The dashed line shows the border of the DR. The boxes represent higher magnification of immunoreactive ERa in the PAG, and of ERb in the lateral part of the DR. Scale bars are 100 mm in lower magnification and 20 mm in higher magnification. Figure 2. Comparison of the expression of tryptophan hydroxylase (TPH) in the DR of male/female (a, b/c, d), young/aged (a, b/c, d) and (wild- type) WT/gene-deficient (a--d/e) mice (n ¼ 5). There is neither sex nor age difference of the number of TPH-positive neurons. However, there is a marked decrease of TPH in estrogen receptor (ER)bÀ/À aged male mice. Meanwhile, there is a marked increase in TPH-positive spindle- shaped cells at the lateral part of the DR of ERbÀ/À aged male mice. **Po0.01 versus WT male, 15 months (M) of age. Scale bar is 100 mmin lower magnification and 20 mm in higher magnification. & 2013 Macmillan Publishers Limited Molecular Psychiatry (2013), 674 -- 680 Estrogen receptor b in the dorsal raphe H Suzuki et al 676 Immunohistochemistry and cell count a 1:200 dilution and incubated with avidin-biotinylated horseradish Paraffin-embedded sections were de-waxed in xylene followed by peroxidase complex (Vector laboratories, Burlingame, CA, USA) for 1 h for rehydration in graded concentrations of ethanol. Antigen retrieval was ERb staining. The slides were developed using DAB (Dako, Carpinteria, CA, achieved by placing slides in 97 1C citrate buffer (pH 6.0) for 10 min. USA) and counterstained with hematoxylin. To count the number of TPH- Endogenous peroxidase was quenched by 30 min incubation in 1% H2O2 in positive cells, six serial sections that included the DR were chosen from 50% methanol followed by blocking of unspecific protein binding with each mouse, and TPH cells were counted in the entire DR and lateral part 3% bovine serum albumin for 10 min. Sections were incubated with of the DR by two independent investigators. The location of the DR and rabbit anti-ERa (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), lateral part of the DR was determined as previously described.17 chicken anti-ERb (1:200 home made) or mouse anti-TPH (1:800, Sigma- Aldrich, St. Louis, MO, USA) in 3% bovine serum albumin with phosphate- buffered saline and 0.1% NP40 at room temperature overnight. The effects of LY3201 on glucose homeostasis Corresponding HRP polymer solution (Bio care medical, Concord, CA, To observe the effects of LY3201 on glucose metabolism, WT male mice USA) was added for 30 min at room temperature for ERa and TPH staining. were administered LY3201 by oral gavage (0.35 mg kgÀ1 per day) for Sections were incubated for 1 h with biotinylated secondary antibodies at 3 days. There were 27 mice in the vehicle-treated and 27 in the LY3201- Figure 3. At the age of 6 months, wild-type (WT) female mice were ovariectomized (OVX). At 1, 3, and 10 weeks (W) after OVX, mice were implanted subcutaneously with placebo, E2 or LY3201 pellets.
Load more

Recommended publications
  • Analysis of Estrogen Receptor Isoforms and Variants in Breast Cancer Cell Lines
    EXPERIMENTAL AND THERAPEUTIC MeDICINE 2: 537-544, 2011 Analysis of estrogen receptor isoforms and variants in breast cancer cell lines MAIE AL-BADER1, CHRISTOPHER FORD2, BUSHRA AL-AYADHY3 and ISSAM FRANCIS3 Departments of 1Physiology, 2Surgery, and 3Pathology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait Received November 22, 2010; Accepted February 14, 2011 DOI: 10.3892/etm.2011.226 Abstract. In the present study, the expression of estrogen domain C, the DNA binding domain; domains D/E, bearing receptor (ER)α and ERβ isoforms in ER-positive (MCF7, both the activation function-2 (AF-2) and the ligand binding T-47D and ZR-75-1) and ER-negative (MDA-MB-231, SK-BR-3, domains; and finally, domain F, the C-terminal domain (6,7). MDA-MB-453 and HCC1954) breast cancer cell lines was The actions of estrogens are mediated by binding to ERs investigated. ERα mRNA was expressed in ER-positive and (ERα and/or ERβ). These receptors, which are co-expressed some ER-negative cell lines. ERα ∆3, ∆5 and ∆7 spliced in a number of tissues, form functional homodimers or variants were present in MCF7 and T-47D cells; ERα ∆5 heterodimers. When bound to estrogens as homodimers, the and ∆7 spliced variants were detected in ZR-75-1 cells. transcription of target genes is activated (8,9), while as heterodi- MDA-MB-231 and HCC1954 cells expressed ERα ∆5 and ∆7 mers, ERβ exhibits an inhibitory action on ERα-mediated gene spliced variants. The ERβ1 variant was expressed in all of the expression and, in many instances, opposes the actions of ERα cell lines and the ERβ2 variant in all of the ER-positive and (7,9).
    [Show full text]
  • Expression of Estrogen Receptor-Beta Isoforms in Barrett's
    ANTICANCER RESEARCH 24: 2919-2924 (2004) Expression of Estrogen Receptor-Beta Isoforms in Barrett’s Metaplasia, Dysplasia and Esophageal Adenocarcinoma LIANG LIU, MINNI CHIRALA and MAMOUN YOUNES Departments of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, U.S.A. Abstract. We have previously shown that the majority of and beta (ER-B). ER-A is mainly expressed in female sex esophageal adenocarcinomas (EA), and its precursor Barrett’s organs, such as breast and uterus (2), whereas ER-B is metaplasia (BM), express estrogen receptor beta (ER-B). Several expressed in both sex organs and other tissues, such as isoforms of ER-B have been described and are presumed to have prostate, lung, thyroid, adrenal cortex and testis (3). Several different functions, but their distribution in BM and EA is not ER-B isoforms have been identified and characterized in known. The aim of this work was to determine which ER-B many non-gynecologic tumors including carcinomas of the isoforms are expressed in EA and BM. Sections of formalin-fixed lung (4), prostate (5), colon (6, 7) and stomach (8). and paraffin-embedded esophageal tissue from 33 esophageactomy Tamoxifen, a specific ER-B antagonist, has been successfully specimens, of which 27 had invasive EA, were stained for the ER- used in the treatment of patients with breast carcinoma B isoforms ER-B1, ER-B2, ER-B3 and ER-B5 utilizing the (9,10) and it has been shown that ER-B status is a significant immunoperoxidase method. ER-B1 was detected in 23 out of 27 predictor of survival in women with breast carcinoma treated (85%) EA compared to 3 out of 14 (21%) Barrett’s metaplasia with mastectomy and adjuvant tamoxifen (11).
    [Show full text]
  • Estrogen Receptor a Binds to Peroxisome Proliferator ^ Activated
    Human Cancer Biology Estrogen Receptor A Binds to Peroxisome Proliferator ^ Activated Receptor Response Element and Negatively Interferes with Peroxisome Proliferator ^ Activated Receptor ; Signaling in Breast Cancer Cells Daniela Bonofiglio,1Sabrina Gabriele,1Saveria Aquila,1Stefania Catalano,1Mariaelena Gentile,2 Emilia Middea,1Francesca Giordano,2 and Sebastiano Ando' 2,3 Abstract Purpose: The molecular mechanisms involved in the repressive effects exerted by estrogen receptors (ER) on peroxisome proliferator ^ activated receptor (PPAR) g^ mediated transcriptional activity remain to be elucidated. The aim of the present study was to provide new insight into the crosstalk between ERa and PPARg pathways in breast cancer cells. Experimental Design: Using MCF7 and HeLa cells as model systems, we did transient trans- fections and electrophoretic mobility shift assay and chromatin immunoprecipitation studies to evaluate the ability of ERa to influence PPAR response element ^ mediated transcription. A pos- sible direct interaction between ERa and PPARg was ascertained by coimmunoprecipitation assay, whereas their modulatory role in the phosphatidylinositol 3-kinase (PI3K)/AKT pathway was evaluated by determining PI3K activity and AKT phosphorylation. As a biological counter- part, we investigated the growth response to the cognate ligands of both receptors in hormone-dependent MCF7 breast cancer cells. Results:Our data show for the first time that ERa binds to PPAR response element and represses its transactivation. Moreover, we have documented the physical and functional interactions of ERa and PPARg, which also involve the p85 regulatory subunit of PI3K. Interestingly, ERa and PPARg pathways have an opposite effect on the regulation of the PI3K/AKT transduction cascade, explaining, at least in part, the divergent response exerted by the cognate ligands 17 h-estradiol and BRL49653on MCF7 cell proliferation.
    [Show full text]
  • Agonists and Knockdown of Estrogen Receptor Β Differentially Affect
    Schüler-Toprak et al. BMC Cancer (2016) 16:951 DOI 10.1186/s12885-016-2973-y RESEARCH ARTICLE Open Access Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro Susanne Schüler-Toprak1*, Julia Häring1, Elisabeth C. Inwald1, Christoph Moehle2, Olaf Ortmann1 and Oliver Treeck1 Abstract Background: Estrogen receptor β (ERβ) is expressed in the majority of invasive breast cancer cases, irrespective of their subtype, including triple-negative breast cancer (TNBC). Thus, ERβ might be a potential target for therapy of this challenging cancer type. In this in vitro study, we examined the role of ERβ in invasion of two triple-negative breast cancer cell lines. Methods: MDA-MB-231 and HS578T breast cancer cells were treated with the specific ERβ agonists ERB-041, WAY200070, Liquiritigenin and 3β-Adiol. Knockdown of ERβ expression was performed by means of siRNA transfection. Effects on cellular invasion were assessed in vitro by means of a modified Boyden chamber assay. Transcriptome analyses were performed using Affymetrix Human Gene 1.0 ST microarrays. Pathway and gene network analyses were performed by means of Genomatix and Ingenuity Pathway Analysis software. Results: Invasiveness of MBA-MB-231 and HS578T breast cancer cells decreased after treatment with ERβ agonists ERB-041 and WAY200070. Agonists Liquiritigenin and 3β-Adiol only reduced invasion of MDA-MB-231 cells. Knockdown of ERβ expression increased invasiveness of MDA-MB-231 cells about 3-fold. Transcriptome and pathway analyses revealed that ERβ knockdown led to activation of TGFβ signalling and induced expression of a network of genes with functions in extracellular matrix, tumor cell invasion and vitamin D3 metabolism.
    [Show full text]
  • The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2020/05/03/mol.120.119776.DC1 1521-0111/98/1/24–37$35.00 https://doi.org/10.1124/mol.120.119776 MOLECULAR PHARMACOLOGY Mol Pharmacol 98:24–37, July 2020 Copyright ª 2020 The Author(s) This is an open access article distributed under the CC BY Attribution 4.0 International license. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells s Philipp Y. Maximov, Balkees Abderrahman, Yousef M. Hawsawi, Yue Chen, Charles E. Foulds, Antrix Jain, Anna Malovannaya, Ping Fan, Ramona F. Curpan, Ross Han, Sean W. Fanning, Bradley M. Broom, Daniela M. Quintana Rincon, Jeffery A. Greenland, Geoffrey L. Greene, and V. Craig Jordan Downloaded from Departments of Breast Medical Oncology (P.Y.M., B.A., P.F., D.M.Q.R., J.A.G., V.C.J.) and Computational Biology and Bioinformatics (B.M.B.), University of Texas, MD Anderson Cancer Center, Houston, Texas; King Faisal Specialist Hospital and Research (Gen.Org.), Research Center, Jeddah, Kingdom of Saudi Arabia (Y.M.H.); The Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois (R.H., S.W.F., G.L.G.); Center for Precision Environmental Health and Department of Molecular and Cellular Biology (C.E.F.), Mass Spectrometry Proteomics Core (A.J., A.M.), Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Mass Spectrometry Proteomics Core (A.M.), and Dan L. Duncan molpharm.aspetjournals.org
    [Show full text]
  • The WT1 Wilms' Tumor Suppressor Gene Product Interacts with Estrogen Receptor-Α and Regulates IGF-I Receptor Gene Transcripti
    135 The WT1 Wilms’ tumor suppressor gene product interacts with estrogen receptor- and regulates IGF-I receptor gene transcription in breast cancer cells Naama Reizner, Sharon Maor, Rive Sarfstein, Shirley Abramovitch, Wade V Welshons1, Edward M Curran1, Adrian V Lee2 and Haim Werner Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel 1Department of Veterinary Biomedical Sciences, University of Missouri, Columbia, Missouri 65211, USA 2Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA (Requests for offprints should be addressed to H Werner; Email: [email protected]) Abstract The IGF-I receptor (IGF-IR) has an important role in breast cancer development and progression. Previous studies have suggested that the IGF-IR gene is negatively regulated by a number of transcription factors with tumor suppressor activity, including the Wilms’ tumor protein WT1. The present study was aimed at evaluating the hypothesis that IGF-IR gene transcription in breast cancer cells is under inhibitory control by WT1 and, furthermore, that the mechanism of action of WT1 involves functional and physical interactions with estrogen receptor- (ER). Results of transient coexpression experiments showed that all four predominant isoforms of WT1 (including or lacking alternatively spliced exons 5 and 9) repressed IGF-IR promoter activity by 39–49%. To examine the potential interplay between WT1 and ER in control of IGF-IR gene transcription we employed ER-depleted C4 cells that were generated by clonal selection of ER-positive MCF-7 cells that were maintained in estrogen-free conditions. IGF-IR levels in C4 cells were |43% of the values in MCF-7 cells whereas WT1 levels in C4 cells were 4·25-fold higher than in MCF-7.
    [Show full text]
  • Oestrogen Receptor α AF-1 and AF-2 Domains Have Cell
    ARTICLE DOI: 10.1038/s41467-018-07175-0 OPEN Oestrogen receptor α AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium Stéphanie Cagnet1, Dalya Ataca 1, George Sflomos1, Patrick Aouad1, Sonia Schuepbach-Mallepell2, Henry Hugues3, Andrée Krust4, Ayyakkannu Ayyanan1, Valentina Scabia1 & Cathrin Brisken 1 α α 1234567890():,; Oestrogen receptor (ER ) is a transcription factor with ligand-independent and ligand- dependent activation functions (AF)-1 and -2. Oestrogens control postnatal mammary gland development acting on a subset of mammary epithelial cells (MECs), termed sensor cells, which are ERα-positive by immunohistochemistry (IHC) and secrete paracrine factors, which stimulate ERα-negative responder cells. Here we show that deletion of AF-1 or AF-2 blocks pubertal ductal growth and subsequent development because both are required for expres- sion of essential paracrine mediators. Thirty percent of the luminal cells are ERα-negative by IHC but express Esr1 transcripts. This low level ERα expression through AF-2 is essential for cell expansion during puberty and growth-inhibitory during pregnancy. Cell-intrinsic ERα is not required for cell proliferation nor for secretory differentiation but controls transcript levels of cell motility and cell adhesion genes and a stem cell and epithelial mesenchymal transition (EMT) signature identifying ERα as a key regulator of mammary epithelial cell plasticity. 1 Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland. 2 Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland. 3 Centre Hospitalier Universitaire Vaudois, Department of Laboratory Medecine, University Hospital of Lausanne, CH-1011 Lausanne, Switzerland.
    [Show full text]
  • Common Single-Nucleotide Polymorphisms in the Estrogen Receptor B Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women
    Published OnlineFirst November 13, 2012; DOI: 10.1158/0008-5472.CAN-12-2484 Cancer Prevention and Epidemiology Research Common Single-Nucleotide Polymorphisms in the Estrogen Receptor b Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women Michael N. Passarelli1,2, Amanda I. Phipps1, John D. Potter1,2,3, Karen W. Makar1, Anna E. Coghill1,2, Karen J. Wernli3,4, Emily White1,2, Andrew T. Chan5,6, Carolyn M. Hutter1,2, Ulrike Peters1,2, and Polly A. Newcomb1,2 Abstract Loss of estrogen receptor b (ERb) expression in the gut is associated with colorectal cancer (CRC) initiation and progression. Germline single-nucleotide polymorphisms (SNP) in genes for the sex-steroid hormone receptors are not strongly associated with CRC risk; however, these SNPs have not previously been evaluated in relation to survival after diagnosis. We enrolled 729 women, ages 50 to 74, diagnosed with invasive CRC between 1997 and 2002 in 13 counties covered by the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry. Participants provided germline DNA. We selected 99 tag-SNPs for the androgen receptor (AR), ERa (ESR1), ERb (ESR2), and progesterone receptor (PGR) genes. Mortality outcomes were ascertained from the National Death Index. During a median of 6.6 years of follow-up, 244 deaths occurred (161 from CRC). We identified 20 SNPs (12 of ESR2 and 8 of PGR) for replication in 1,729 women diagnosed with incident invasive CRC (555 deaths; 405 from CRC) from three prospective cohort studies that participate in the Genetics and Epidemiology of Colorectal Cancer Consortium. Three correlated SNPs in the promoter of ESR2 (rs2987983, rs3020443, and rs2978381) were statistically significant predictors of CRC-specific and overall survival.
    [Show full text]
  • Irf1) Signaling Regulates Apoptosis and Autophagy to Determine Endocrine Responsiveness and Cell Fate in Human Breast Cancer
    INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER A Dissertation Submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Physiology & Biophysics By Jessica L. Roberts, B.S. Washington, DC September 27, 2013 Copyright 2013 by Jessica L. Roberts All Rights Reserved ii INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER Jessica L. Roberts, B.S. Thesis Advisor: Robert Clarke, Ph.D. ABSTRACT Interferon regulatory factor-1 (IRF1) is a nuclear transcription factor and pivotal regulator of cell fate in cancer cells. While IRF1 is known to possess tumor suppressive activities, the role of IRF1 in mediating apoptosis and autophagy in breast cancer is largely unknown. Here, we show that IRF1 inhibits antiapoptotic B-cell lymphoma 2 (BCL2) protein expression, whose overexpression often contributes to antiestrogen resistance. We proposed that directly targeting the antiapoptotic BCL2 members with GX15-070 (GX; obatoclax), a BH3-mimetic currently in clinical development, would be an attractive strategy to overcome antiestrogen resistance in some breast cancers. Inhibition of BCL2 activity, through treatment with GX, was more effective in reducing the cell density of antiestrogen resistant breast cancer cells versus sensitive cells, and this increased sensitivity correlated with an accumulation of autophagic vacuoles. While GX treatment promoted autophagic vacuole and autolysosome formation, p62/SQSTM1, a marker for autophagic degradation, levels accumulated.
    [Show full text]
  • Correlation of Wilms' Tumor 1 Isoforms with HER2 and ER-Α and Its Oncogenic Role in Breast Cancer
    ANTICANCER RESEARCH 34: 1333-1342 (2014) Correlation of Wilms’ Tumor 1 Isoforms with HER2 and ER-α and its Oncogenic Role in Breast Cancer TAPANAWAN NASOMYON1, SRILA SAMPHAO2, SURASAK SANGKHATHAT2, SOMRIT MAHATTANOBON2 and POTCHANAPOND GRAIDIST1 Departments of 1Biomedical Sciences and 2Surgery, Faculty of Medicine, Prince of Songkla University, Hat-Yai, Songkhla, Thailand Abstract. Background: Wilms’ tumor 1 (WT1) gene has solid tumors, such as those of the lung (2) and breast (3-5), different functional properties depending on the isoform type. and other non-solid tumors such as leukemia (6-8). This has This gene correlates with cell proliferation in various types raised the possibility that WT1 could have tumorigenic of cancer. Here, we investigated the expression of WT1 activity rather than tumor-suppressor activity (9-13). isoforms in breast cancer tissues, and focused on the Moreover, WT1 mRNA and protein are expressed in nearly oncogenic role through estrogen receptor-alpha (ER-α) and 90% of breast carcinoma tissues but with low detection in human epidermal growth factor receptor 2 (HER2). adjacent normal breast samples (3). High expression levels Materials and Methods: Expression of WT1(17AA+) and of WT1 mRNA are related to poor prognosis of breast cancer (17AA−) was investigated in adjacent normal breast and (14) and leukemia (7). These phenomena could be due to a breast cancer using Reverse transcription-polymerase chain growth and survival effect from WT1. In addition, down- reaction and western blotting. The correlation of WT1 regulation of WT1 inhibits breast cancer cell proliferation isoforms with HER2 and ER-α was examined using MCF-7 (11).
    [Show full text]
  • Estrogenically Regulated LRP16 Interacts with Estrogen Receptor a and Enhances the Receptor’S Transcriptional Activity
    Endocrine-Related Cancer (2007) 14 741–753 Estrogenically regulated LRP16 interacts with estrogen receptor a and enhances the receptor’s transcriptional activity W-D Han1, Y-L Zhao1, Y-G Meng 2, L Zang 3, Z-Q Wu1,QLi1, Y-L Si1, K Huang 2, J-M Ba3, H Morinaga4, M Nomura4 and Y-M Mu3 Departments of 1Molecular Biology, Institute of Basic Medicine, 2Obstetrics and Gynecology and 3Endocrinology, Chinese PLA General Hospital, Beijing 100853, China 4Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan (Correspondence should be addressed to Y-M Mu; Email: [email protected]) Abstract Previous studies have shown that leukemia related protein 16 (LRP16) is estrogenically regulated and that it can stimulate the proliferation of MCF-7 breast cancer cells, but there are no data on the mechanism of this pathway. Here, we demonstrate that the LRP16 expression is estrogen dependent in several epithelium-derived tumor cells. In addition, the suppression of the endogenous LRP16 in estrogen receptor a (ERa)-positive MCF-7 cells not only inhibits cells growth, but also significantly attenuates the cell line’s estrogen-responsive proliferation ability. However, ectopic expression of LRP16 in ERa-negative MDA-MB-231 cells has no effect on proliferation. These data suggest the involvement of LRP16 in estrogen signaling. We also provide novel evidence by both ectopic expression and small interfering RNA knockdown approaches that LRP16 enhances ERa-mediated transcription activity. In stably LRP16-inhibitory MCF-7 cells, the estrogen-induced upregulation of several well-known ERa target genes including cyclin D1 and c-myc is obviously impaired.
    [Show full text]
  • The Estrogen Receptor- -Induced Microrna Signature Regulates Itself
    The estrogen receptor-␣-induced microRNA signature regulates itself and its transcriptional response Leandro Castellanoa,1, Georgios Giamasa, Jimmy Jacoba, R. Charles Coombesa, Walter Lucchesib, Paul Thiruchelvama, Geraint Bartonc, Long R. Jiaod, Robin Waite, Jonathan Waxmana, Gregory J. Hannonf, and Justin Stebbinga,1 aDepartment of Oncology, Cyclotron Building, Hammersmith Hospital Campus, Imperial College, Du Cane Road, London W12 0NN, United Kingdom; bDepartment of Cellular and Molecular Science, Burlington Dane’s Building, Hammersmith Hospital Campus, Imperial College, Du Cane Road, London W12 0NN, United Kingdom; cCentre for Bioinformatics, Division of Molecular Biosciences, Faculty of Natural Sciences, Biochemistry Building, South Kensington Campus, Imperial College, London SW7 2AZ, United Kingdom; dDivision of Surgery, Oncology, Reproductive Biology and Anaesthesia, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, United Kingdom; eThe Kennedy Institute, Faculty of Medicine, Imperial College, Charing Cross Hospital Campus, London W6 8LH, United Kingdom; and fWatson School of Biological Sciences, Howard Hughes Medical Institute, Cold Spring Harbor Laboratory (CSHL), 1 Bungtown Road, Cold Spring Harbor, NY 11724 Edited by Bert W. O’Malley, Baylor College of Medicine, Houston, TX, and approved July 22, 2009 (received for review June 24, 2009) Following estrogenic activation, the estrogen receptor-␣ (ER␣) di- 70-nt ‘‘imperfect’’ stem loop RNA actively transported into the rectly regulates the transcription of target genes via DNA binding. cytoplasm. In the cytoplasm the pre-miRNA is cleaved by DICER, MicroRNAs (miRNAs) modulated by ER␣ have the potential to fine a dual processing event that releases a small double stranded RNA, tune these regulatory systems and also provide an alternate mech- about 22 nt in length.
    [Show full text]